SecBot SecBot
Biotech Drug Report Generated Nov 6, 2026

ARV-806

ARVN·ARVINAS, INC.
BEARISH
Drug Impact Rating3/10
Trial phase
Phase 1/2
Time to market
ARV-806 is in Phase 1 dose escalation with no internal Phase 2/3 plans; the company is seeking an out-licensing partner for further development. Even if partnered, approval would likely be many years away given the early stage and competitive landscape.
Why 3/10
ARV-806 has no confirmed hard dated binary catalyst in the next ~12 months. The Phase 1 data readout was previously guided for H2 2026 but was removed from the milestone schedule in the Q3 2026 earnings call (Nov 3, 2026). The company is seeking to out-license the asset, making any future catalyst dependent on a partner. ImpactScore is 3 because this is an early-stage, deprioritized asset at a company with multiple other programs including an approved product.
Actionable Insight BEARISH

The next catalyst for ARV-806 is the Phase 1 monotherapy dose escalation data readout, which was previously guided for the second half of 2026 but was removed from the milestone schedule in the Q3 2026 earnings call (Nov 3, 2026). If data are released, positive results could attract a licensing partner; negative or underwhelming data would likely make out-licensing difficult and confirm the asset's diminished value within Arvinas. The stock already trades near its 52-week low, reflecting this de-prioritization.

Price Chart

Loading chart...

Executive Summary

ARV-806 is an investigational PROTAC drug designed to degrade the mutant KRAS G12D protein, a common driver of pancreatic, colorectal, and lung cancers. It is in a Phase 1/2 first-in-human clinical trial (NCT07023731) that started in May 2025. However, Arvinas has significantly deprioritized this asset: it completed dose escalation enrollment but plans to out-license any further development. In the Q3 2026 earnings call (Nov 3, 2026), ARV-806 was removed from the corporate pipeline chart and milestone schedule, with management instead highlighting three other pipeline programs. Meanwhile, competitor Astellas has advanced its own KRAS G12D degrader (ASP3082/setidegrasib) into Phase 3 trials. ARVN stock dropped ~11.7% on Nov 5, 2026 to $6.55, near its 52-week low, reflecting market disappointment with the pipeline reprioritization.

How It Works

ARV-806 is a PROTAC (PROteolysis TArgeting Chimera) drug, a type of molecule that works like a garbage disposal for a specific cancer-causing protein. One end of the molecule grabs onto the mutant KRAS G12D protein (a common driver of pancreatic, colorectal, and lung cancers), while the other end recruits the cell's natural protein-disposal system (the proteasome). This forces the cell to tag and destroy the mutant KRAS protein, eliminating it entirely. Unlike traditional cancer drugs that simply block a protein's activity, PROTACs remove the protein itself.

Trial Status

The Phase 1/2 first-in-human study (NCT07023731) began May 29, 2025, targeting 76 patients across 14 sites. Dose escalation enrollment in Phase 1 was completed as of Q1 2026. The trial was last updated September 2026 and is estimated to complete by November 30, 2026. A trial-in-progress poster was presented at ASCO-GI 2026. Preclinical data presented at AACR-NCI-EORTC (Oct 2025) showed sub-nanomolar KRAS G12D degradation potency and >25-fold improved anti-proliferative activity versus inhibitors and another clinical degrader.

The Two-Sided Case

▲ Bull Case5
ARV-806 demonstrated sub-nanomolar potency for degrading KRAS G12D and >25-fold greater anti-proliferative potency versus inhibitors and another clinical-stage degrader in preclinical studies (AACR-NCI-EORTC Oct 2025).
KRAS G12D is the most common KRAS mutation and a high-value target in pancreatic, colorectal, and lung cancers with no approved therapies yet, representing a large unmet need.
Arvinas has a strong PROTAC platform validated by the FDA approval of VEPPANU (vepdegestrant), the first approved PROTAC drug.
The company has $558.9M in cash with runway into H2 2028, providing ample time to find a licensing partner for ARV-806.
Analyst consensus on ARVN is mixed but includes 13 Buy/Strong Buy ratings with a mean price target of $14.46 (94.9% implied upside from $7.42).
▼ Bear Case5
Arvinas removed ARV-806 from its corporate pipeline chart and milestone schedule in the Q3 2026 earnings call (Nov 3, 2026), signaling internal de-prioritization. The CEO highlighted BCL6, polyQ-AR, and HPK1 programs instead.
The company plans to out-license any further ARV-806 development beyond Phase 1 dose escalation, meaning future value depends on finding a partner, not internal execution.
Astellas' ASP3082 (setidegrasib), a competing KRAS G12D degrader, has already advanced to Phase 3 in NSCLC and pancreatic cancer, putting ARV-806 significantly behind.
ARVN stock dropped ~11.7% on Nov 5, 2026 to $6.55, near its 52-week low of $6.52, reflecting market disappointment with the pipeline reprioritization.
No approved therapies currently target KRAS G12D, but the competitive landscape is crowded with multiple inhibitors and degraders in development.

Upcoming Catalysts

  • Phase 1 monotherapy dose escalation data readout (previously guided for H2 2026, but removed from milestone schedule in Q3 2026 earnings)
  • Potential out-licensing or partnership agreement for further ARV-806 development

Source Filing

The SecBot filing or press-release report that triggered this drug report:

ARVINAS, INC. S-3 ARVN ·Originating report

Sources · 12

Hover a chip for the title
1 arvinas.com2 biospace.com3 x.com4 ascopubs.org5 ir.arvinas.com6 ir.arvinas.com7 stocktitan.net8 aacrjournals.org9 dashboard.datalookout.com10 newsroom.astellas.com11 tipranks.com12 clinicaltrials.gov